PRGO
NYSE · Pharmaceuticals
Perrigo Co Plc
$15.83
+0.13 (+0.83%)
Financial Highlights (FY 2026)
Revenue
4.25B
Net Income
-1,423,646,230
Gross Margin
35.1%
Profit Margin
-33.5%
Rev Growth
-1.5%
D/E Ratio
1.24
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 35.1% | 35.1% | 30.7% | 30.7% |
| Operating Margin | -27.2% | -24.5% | 18.2% | 20.0% |
| Profit Margin | -33.5% | -31.8% | 17.4% | 17.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.25B | 4.31B | 733.03M | 632.45M |
| Gross Profit | 1.49B | 1.52B | 225.36M | 194.44M |
| Operating Income | -1,154,569,794 | -1,055,043,978 | 133.71M | 126.60M |
| Net Income | -1,423,646,230 | -1,300,925,583 | 127.46M | 109.75M |
| Gross Margin | 35.1% | 35.1% | 30.7% | 30.7% |
| Operating Margin | -27.2% | -24.5% | 18.2% | 20.0% |
| Profit Margin | -33.5% | -31.8% | 17.4% | 17.4% |
| Rev Growth | -1.5% | -1.5% | +2.0% | -3.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 604.20M | 604.20M | 149.00M | 136.39M |
| Total Equity | 487.22M | 487.22M | 768.79M | 740.72M |
| D/E Ratio | 1.24 | 1.24 | 0.19 | 0.18 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -817,292,480 | -788,331,664 | 189.96M | 150.29M |
| Free Cash Flow | — | — | 136.11M | 128.72M |